Several others have shown similar results and implicated TGFβ signatures in resistance to ICIs in a multiplicity of cancer entities [69, 91], as well as improved T cell penetration in the tumour upon TGFβ inhibition [40, 91, 92]. This evidence concerns the gene TGFB1 and neoplasm.